The biotech's numbers are meaningless, but an update on one of its programs sent the stock down.
All eyes will be on the biotech behemoth's quarterly report this Thursday.
Can the quick growing maker of Eylea beat an aging biotech behemoth?
Our healthcare contributors think these five stocks might be on big pharma's shopping list.
The emergence of biosimilars leads to a shocking FDA panel decision that I guarantee you've never seen before.
AbbVie's guidance suggests that the threat from biosimilars isn't too scary... at least for now.
Motley Fool contributors target three biotechs that could energize your portfolio in 2016.
AbbVie's CEO discusses its three most important products, three key pipeline drugs, and what catalysts shareholders should keep their eyes on in 2016.
It was another rough week for healthcare ETFs, but this fund held up better than the rest.
Guidance for $37 billion in sales in 2020 suggests that AbbVie can sidestep threats of a generic Humira.